Cassava Sciences' Simufilam Trial Halted by FDA
ByAinvest
Friday, Dec 19, 2025 11:37 am ET1min read
SAVA--
Cassava Sciences' trial for simufilam in tuberous sclerosis complex-related epilepsy has been placed on full clinical hold by the FDA. The company needs to provide additional information and modify the protocol design. The updated timing for trial initiation depends on the company's ability to provide the requested information and the FDA's review. Cassava has $106.1 million in cash and cash equivalents, expected to support operations into 2027.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet